MOUNTAIN VIEW, Calif.,
July 29, 2014 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today
that it is participating in two healthcare conferences during the
third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference
and the Morgan Stanley Global Healthcare 2014 Conference.
Alexza's corporate presentation will be webcast live from the
Morgan Stanley Conference. The details on each event are
below:
- 2014 Avondale Partners Healthcare 1-1 Conference, Monday, August 11, 2014 in Boston, MA. The format is limited to
one-on-one meetings with investors and there is no webcast from
this conference.
- Morgan Stanley Global Healthcare Conference 2014, September 8 - 10, 2014 in New York, NY. The Company's corporate
presentation will be on Tuesday, September
9th at 9:10 am ET.
The webcast of the presentation may be accessed from the
Investor Relations section of the Alexza Pharmaceuticals website at
www.alexza.com. A replay of the Morgan Stanley Healthcare
Conference presentation will be available for 30 days on the
Investor Relations section of Alexza's website approximately 24
hours after the presentation.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development
and commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE® is Alexza's first commercial product and it
has been approved for sale by the U.S. Food and Drug
Administration, and the European Commission. Teva
Pharmaceuticals USA, Inc. is
Alexza's commercial partner for ADASUVE in the U.S. Ferrer is
Alexza's commercial partner for ADASUVE in Europe, Latin
America and the Commonwealth of Independent States
countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties. Any
statement describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and our partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues and
royalties associated with the sale of ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2013 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.